A comprehensive guide to early pregnancy screening: part 1

Written in association with: Dr Panicos Shangaris
Published: | Updated: 09/08/2023
Edited by: Aoife Maguire

Early pregnancy care is extremely important in determining the health of both mother and baby and various tests can be carried out to establish any potential health issues during the baby’s development. In the first article of a two-part series esteemed consultant in obstetrics and maternal and fetal medicine, Dr Panicos Shangaris explains these tests and explains how these tests work and which potential health issues they can identify.  

 

 

 

What are the recommended screening tests during the early stages of pregnancy to assess the health of both the mother and the developing foetus?

 

Early pregnancy is an extremely important time for screening tests to ensure the health of both the mother and the developing foetus. Some recommended tests are as follows:

 

Pregnancy Confirmation Test

 

The first step is a pregnancy test, which is usually a urine or blood test. This test will confirm the pregnancy.

 

Dating Ultrasound

 

An early ultrasound may be performed to confirm the pregnancy location (to rule out an ectopic pregnancy), determine if there are multiple pregnancies and to confirm the gestational age and due date.

 

Blood Tests

 

A full blood count (FBC) will be used to detect if the expectant mother has anaemia. It determines both the blood type and Rh factor and if the mother is Rh-negative, she may need treatment to prevent Rh sensitisation.

 

If the mother’s immunisation status is unknown, tests for immunity to rubella (German measles) and chickenpox (varicella) are done. A test for syphilis, hepatitis B, and HIV may also be performed.

 

Urine Test

 

A urine test checks for urinary tract infections, kidney disease, and diabetes.

 

Screening for Gestational Diabetes

 

High-risk women (such as those who are overweight or have a family history of diabetes) may be screened early for gestational diabetes.

 

Genetic Screening

 

Depending on the woman's family history or ethnic background, certain genetic screenings may be recommended, such as carrier screening for conditions like cystic fibrosis or spinal muscular atrophy. Non-invasive prenatal testing (NIPT) can be done as early as 10 weeks to screen for Down syndrome and other chromosomal abnormalities.

 

Early Genetic Diagnostic Tests

For pregnancies at higher risk of genetic or chromosomal conditions, invasive diagnostic tests like chorionic villus sampling (CVS) may be performed in the first trimester. This test can diagnose certain conditions, but expectant mothers must be wary because it carries a small risk of miscarriage.

 

Screening for Infectious Diseases

 

In addition to those previously mentioned, women may be screened for other infectious diseases such as tuberculosis and sexually transmitted infections, including gonorrhoea and chlamydia, based on their risk factors.

 

These tests provide valuable information about both the mother’s and the developing foetus’s health. These tests must be discussed in detail with the healthcare provider, as the necessity can vary greatly depending on individual health histories, risk factors, and personal preferences.

 

What is the purpose of prenatal genetic screening tests, and what conditions do they typically screen for?

 

Prenatal genetic screening tests provide information about the likelihood of the foetus having certain genetic conditions. They are optional and can give expectant parents valuable information about the health of their developing baby. However, these tests do not provide definitive answers, they only have the ability to estimate the chances of a baby having certain genetic disorders.

 

The following conditions are commonly tested for through testing:

 

Down Syndrome (Trisomy 21)

 

Down syndrome is caused by an extra copy of chromosome 21. It's associated with intellectual disability and characteristic physical features. It may lead to heart defects and other health problems.

 

Edwards Syndrome (Trisomy 18) and Patau Syndrome (Trisomy 13)

 

These conditions develop due to an extra copy of chromosome 18 or 13, respectively. They are associated with severe intellectual disability and physical problems, and most babies with these conditions do not survive beyond infancy.

 

Open Neural Tube Defects, such as Spina Bifida

 

The spine, spinal cord, or brain defects occur when the neural tube doesn't close properly. This can lead to varying degrees of disability, including physical and intellectual.

 

Certain inherited genetic disorders

 

Depending on the parents’ family history or ethnicity, the foetus may be at greater risk of developing certain diseases, such as cystic fibrosis, Tay-Sachs disease, or sickle cell disease, therefore specific tests can be carried out according to the disease which of which the baby is at higher risk.

 

 

Different tests are available through the various stages of pregnancy.

 

 

First Trimester Screening:

 

This screening normally takes place between 11 and 14 weeks. It involves a blood test and an ultrasound examination called the nuchal translucency screening, which measures the thickness of space at the back of the baby's neck. This screening test can estimate the baby's risk of Down syndrome and trisomies 13 and 18.

 

Non-Invasive Prenatal Testing (NIPT)

Usually done after 10 weeks, this blood test analyses fragments of the baby's DNA in the mother's blood to screen for Down syndrome, trisomy 18, trisomy 13, and sex chromosome abnormalities.

 

Second Trimester Screening (Quad Screen)

 

This test usually takes place between 15 and 20 weeks and screens for four substances in a woman's blood to estimate the risk of Down syndrome.

 

As previously mentioned, it is important to remember that screening tests do not provide a diagnosis; they only provide a risk assessment. If screening tests indicate a higher risk, diagnostic tests such as amniocentesis can be performed to diagnose or rule out specific genetic conditions.

 

It is essential for every pregnant woman to have a detailed discussion with her healthcare provider to understand the benefits, risks, and limitations of these screenings and to decide which tests, if any, are right for her. The decision to have genetic screening is personal and should be based on the individual's values, concerns, and needs.

 

 

 

 

If you are pregnant and would like to book an appointment with Dr Shangaris, do not hesitate to do so by visiting his Top Doctors profile today.

By Dr Panicos Shangaris
Obstetrics & gynaecology

Dr Panicos Shangaris is a highly skilled consultant in obstetrics and maternal and foetal medicine in London. With over 15 years of experience, Dr Shangaris' dedicated clinical expertise specialises in all aspects of fetal medicine, pregnancy, high-risk pregnancy, prenatal diagnosis, preconception counselling, birthing control, and medicolegal cases.

In addition to his roles within the NHS and academic sectors at King's College, Dr Shangaris provides an extensive range of private maternity care services. These services include in-person consultations as well as video e-consultations. His private offerings span comprehensive antenatal care, featuring additional tests such as non-invasive prenatal testing (NIPT), as well as a range of birthing options that include both private caesarean sections and normal vaginal deliveries. His transparent fee pricing ensure patients understand the costs. 

Dr Shangaris graduated from the Royal College of Surgeons in Ireland in 2005 and completed his foundation training in East Lancashire. He then pursued higher specialist training in London at renowned institutions such as University College London, the Royal Free London, Barnet, and North Middlesex Hospitals.

He obtained a Master's degree in foetal medicine and prenatal genetics at University College London (UCL) with distinction. Notably, he was awarded the prestigious Wellcome Trust SPARKS research training fellowship in 2011, which allowed him to undertake his PhD research at UCL. His research focuses on treating genetic blood disorders through foetal stem cell transplantation or gene therapy.

Dr Shangaris has received additional funding from esteemed organisations like the Academy of Medical Sciences, the National Institute for Health and Care Research, and the Fetal Medicine Foundation to further his clinical research endeavours. During his subspecialty training in maternal and fetal Medicine at St Thomas' and King's College Hospitals, he worked under the guidance of prominent experts in the field. He gained expertise in specialised clinics such as complex fetal medicine, fetal urology, gestational diabetes, hypertension in pregnancy, multiple pregnancy, fetal cardiology, genetics, and perinatal pathology.

Dr Shangaris holds the position of maternal and fetal medicine consultant at King's College Hospital NHS Foundation Trust and a Senior Clinical Lecturer at King's College London. He is also an academic co-lead for the BRC DTP PhD programme and supervises research projects for BSc, MSc, and PhD students.

With a commitment to collaborative research, Dr Shangaris actively contributes to maternal and fetal medicine clinical research, leading to numerous publications in peer-reviewed journals. He is part of the editorial team at the Reproductive Science Journal and holds the position of president of the Royal Society of Medicine, Maternity and Newborn Forum, further showcasing his leadership role in the field.

View Profile

Overall assessment of their patients


  • Related procedures
  • Platelet-rich plasma
    Sexually transmitted infections (STIs)
    Cosmetic Consulting
    Labiaplasty
    Vaginoplasty
    Breast reconstruction
    Congenital malformations
    Sexual dysfunction
    Laparoscopy
    Erectile dysfunction
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.